GlassScriptPhysician profile
Issac Grinberg
NPI 1790768257
$9,530.32
in general payments reported to CMS, 2019-2025
27 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,863 · 2020: $834 · 2021: $1,321 · 2022: $827 · 2023: $1,651 · 2024: $1,180 · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,684.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,279.17 | 2019-2025 | Amplatzer Amulet, Ensite, Gallant |
| Boston Scientific Corporation | $811.86 | 2019-2025 | Watchman Access System, Farapulse |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $562.12 | 2019-2025 | Lifevest |
| Medtronic, INC. | $473.90 | 2021-2025 | Corevalve Evolut R, Symplicity G3, V-Loc 180 |
| Novartis Pharmaceuticals Corporation | $405.91 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $320.93 | 2022-2025 | Assure Wcd |
| Medtronic Vascular, INC. | $309.32 | 2019 | |
| Janssen Pharmaceuticals, INC | $209.30 | 2019-2022 | |
| Amgen INC. | $162.36 | 2023-2025 | Repatha, Repatha |
| Inari Medical, INC. | $161.71 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| E.R. Squibb & Sons, L.L.C. | $150.82 | 2019-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.74 | 2019 | |
| Siemens Medical Solutions USA, INC. | $112.25 | 2019-2020 | |
| Chiesi USA, INC. | $88.08 | 2025 | Cleviprex |
| Edwards Lifesciences Corporation | $67.87 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $60.24 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $40.60 | 2025 | Verquvo |
| Astellas Pharma US INC | $36.45 | 2019 | |
| Impulse Dynamics (USA) INC. | $30.87 | 2023 | Optimizer |
| Cordis US Corp. | $19.45 | 2025 | Mynx Control Venous |
| Actelion Pharmaceuticals US, INC. | $18.14 | 2019 | |
| Teleflex LLC | $17.07 | 2023 | Manta |
| Sanofi-Aventis U.S. LLC | $14.95 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $14.91 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $14.39 | 2024 | Brilinta |
| Pfizer INC. | $11.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Issac Grinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.